Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This article discusses the temporary scalp trichopigmentation procedure, detailing its unique approach compared to traditional scalp micropigmentation, and reports no new clinical findings.

This phase I study reported that ETC-159, targeting Wnt signalling, showed tolerable safety profiles at doses that inhibit its pathway, though bone turnover markers increased, warranting early and regular monitoring. No tumor responses were observed, but two patients achieved stable disease for several cycles.

In this case report, a 13-year-old girl with Pitt-Hopkins syndrome developed hair curling after starting the antiepileptic drug perampanel, which had not been previously reported as a side effect.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

This study found that prostaglandin E2 pretreatment may reduce radiotherapy-induced alopecia by enhancing hair follicle self-repair through transient G1 arrest, suggesting a potential preventive treatment.

Prostaglandin helps regenerate hair follicles after radiation damage.

This article reviews the condition plica neuropathica, including its manifestations, potential causes, and treatment, but it does not provide new clinical findings.

This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.

This retrospective study observed no significant difference in the prevalence of incidental prostate cancer between suprapubic prostatectomy and transurethral prostate resection groups, with most tumors being well differentiated and early-stage.

This study compared the effectiveness of platelet-rich plasma and 5% topical minoxidil for androgenetic alopecia in men but did not report conclusive clinical results, relying on patient self-assessments.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This review discusses diagnostic tools for scarring alopecias, emphasizing trichoscopy as a low-cost, non-invasive method for more accurate diagnosis, although it reports no new clinical results.

This study reported that the PTGER2 gene is strongly expressed in cashmere goat skin and its expression tends to decrease from the anagen to telogen stages of the hair follicle cycle.

This study found that liarozole is more effective than cyproterone acetate for improving PSA response and survival in metastatic prostate cancer after first-line endocrine therapy, while maintaining quality of life.

In this study, researchers developed a promising transdermal agent using Triton X-100-modified polyethyleneimine that successfully delivered genetic material to hair follicle cells in mice, potentially alleviating hair loss due to androgenetic alopecia by promoting cell proliferation and inhibiting apoptosis.

This study observed that PCOS presents frequently with cutaneous symptoms and affects both obese and non-obese women, highlighting the importance of interdisciplinary care for effective management.

This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This review examines the use and efficacy of Panax ginseng in various clinical settings, noting that clinical trial outcomes vary widely based on study conditions and ginseng types; no new results are reported.

This question-based abstract lists potential survey questions regarding contraception, hormone therapy, and related health issues but presents no new research findings.

In this study, the researchers found that glycerol strongly influenced the physical characteristics of an anti hair loss cream containing Saw Palmetto extract, notably improving its spreadability, viscosity, and stability without causing skin irritation.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This study found that polyacetylene compounds in Panax ginseng extracts may inhibit neurotrophin receptor binding, suggesting potential therapeutic benefits for alopecia and other hair growth disorders.

This study observed that the Pilogics Hairegen device increased total hair count by 23.2% and terminal hair count by 21.1% in 289 patients with androgenetic alopecia after approximately 20 weeks of use, with no adverse effects reported.